A heart failure diagnosis is rarely made from symptoms alone. It rests on three things put side by side: what you feel, what a blood test shows, and what an ultrasound of your heart measures. That combination matters, because breathlessness, swollen ankles and fatigue have many possible explanations.
In this article you will learn how clinicians move from suspicion to a confirmed diagnosis, what BNP and NT-proBNP levels mean and where the usual cut points sit, why your ejection fraction places you in one of three treatment groups, which drug classes form the backbone of care, and which blood tests get repeated once medication starts. The aim is to make your own lab report readable.
What a heart failure diagnosis actually involves
Heart failure does not mean the heart has stopped. It means the heart cannot pump enough blood and oxygen to meet the body’s needs, either because the muscle squeezes too weakly or because it has become too stiff to fill. The Centers for Disease Control and Prevention estimates that about 6.7 million American adults live with the condition.
The three pillars of the assessment
A heart failure diagnosis is built from converging evidence rather than a single result:
- Clinical evaluation: symptom history, walking distance, whether you need extra pillows at night, and an exam looking for swelling, neck vein distension and lung crackles.
- A natriuretic peptide blood test: BNP or NT-proBNP, which rise when the heart chambers are stretched.
- Cardiac imaging: usually an echocardiogram, an ultrasound measuring how the chambers move and how much blood each beat ejects.
Why symptoms alone are not enough
Shortness of breath on exertion is one of the least specific complaints in medicine. Anemia, thyroid disease, obesity, deconditioning, lung disease and anxiety all produce it, and ankle swelling can come from veins, kidneys, liver or a medication. That overlap is why a blood marker reflecting cardiac wall stress is useful early. People investigating fatigue and breathlessness often also read a complete guide to anemia symptoms and causes.
BNP and NT-proBNP: the blood tests that open the door
When the walls of the heart are stretched, cardiac cells release a precursor hormone that splits into two fragments: active BNP, which promotes salt and water excretion, and the inactive fragment NT-proBNP. Laboratories measure either one. According to MedlinePlus, these tests exist mainly to confirm or rule out heart failure in people who already have symptoms, and secondarily to gauge severity.
Rule-out and rule-in thresholds
The most useful property of these markers is that a low result makes heart failure unlikely. Cut points differ depending on whether you are seen in an emergency department with sudden breathlessness or in a clinic with a slower complaint. The values below follow current consensus guidance for a suspected heart failure diagnosis.
| Setting | BNP rule-out | NT-proBNP rule-out | How the result is read |
|---|---|---|---|
| Non-acute, symptoms developing over weeks (clinic or primary care) | Below 35 pg/mL | Below 125 pg/mL | Untreated heart failure is unlikely; look for another cause |
| Acute, sudden breathlessness (emergency department) | Below 100 pg/mL | Below 300 pg/mL | Acute heart failure is unlikely; investigate lung and other causes |
| Above the cut point | Raised | Raised | Heart failure is possible; an echocardiogram is the next step, not a conclusion |
Two points follow. BNP and NT-proBNP are not interchangeable: NT-proBNP circulates longer and runs several times higher, so never read one against the other’s reference range. And a raised result is a prompt for imaging, not a diagnosis. Readers who want the detail of each assay can consult a detailed guide to BNP blood test results and the reference ranges for NT-proBNP results.
What shifts these levels independently of the heart
Several conditions push natriuretic peptides up without any pump problem: reduced kidney function, atrial fibrillation, advanced age, anemia and severe lung disease. One factor pushes them down: excess body weight is linked to lower levels, so a person with obesity can have a falsely reassuring value. Kidney function is the commonest confounder, which is why creatinine is measured alongside. We also publish a detailed guide to chronic kidney disease.
Ejection fraction and the three heart failure classes
If the blood test points toward the heart, an echocardiogram follows. Its central output is the left ventricular ejection fraction, the percentage of blood the main pumping chamber pushes out with each beat; a normal value sits roughly between 55 and 70 percent. It does not measure how sick you feel, but it determines which drugs have proven benefit, so it organizes modern care.
| Class | Ejection fraction | What is happening | Treatment implication |
|---|---|---|---|
| HFrEF, reduced ejection fraction | 40 percent or below | The muscle contracts too weakly | The strongest evidence base; four foundational drug classes apply |
| HFmrEF, mildly reduced ejection fraction | 41 to 49 percent | An intermediate group that can move in either direction | Much of the reduced-fraction approach is applied, with individual judgment |
| HFpEF, preserved ejection fraction | 50 percent or above | The chamber squeezes normally but is stiff and fills poorly | Fewer proven drugs; treating blood pressure, weight and diabetes matters most |
| HFimpEF, improved ejection fraction | Now above 40 percent after previously being 40 percent or below | The muscle has recovered function on treatment | Therapy is normally continued, because stopping often causes relapse |
How the measurement is taken, and why it moves
Ejection fraction is estimated from ultrasound images, with a margin of error of several percentage points between operators and visits, so a shift from 48 to 52 percent may reflect measurement variation rather than real change. Cardiac magnetic resonance imaging gives a more reproducible figure when the echocardiogram is unclear.
Preserved does not mean mild
Roughly half of those diagnosed have a preserved ejection fraction, with hospitalization rates comparable to the reduced group. The label describes a mechanism, not a severity. Readers wanting the wider picture can consult our overview of congestive heart failure.
The rest of the diagnostic workup
Blood tests ordered alongside natriuretic peptides
A first panel typically covers a complete blood count, kidney function with electrolytes, liver enzymes, HbA1c, thyroid function, iron studies and a lipid profile. Anemia and thyroid disease can imitate heart failure, iron deficiency is treatable, and diabetes changes which medications are prioritized. Anyone reviewing their glucose control can read a guide to glycated hemoglobin results, and we also explain TSH blood test results.
Troponin may also be measured. It reflects injury to heart muscle cells, but mildly raised values are common in chronic heart failure and do not automatically mean a heart attack. For more detail, read a full explanation of troponin blood test results.
Imaging and electrical tests
An electrocardiogram looks for rhythm disturbances and conduction delay, and a chest X-ray shows fluid in the lungs and heart size. Depending on the suspected cause, clinicians may add coronary angiography, cardiac magnetic resonance imaging or a stress test. Mayo Clinic sets out the full diagnostic and treatment pathway for heart failure.
Guideline-directed medical therapy, explained
Guideline-directed medical therapy is the drug combination shown in trials to reduce hospitalizations and deaths. For reduced ejection fraction it rests on four classes, usually started together at low doses and increased over weeks.
- A renin-angiotensin blocker: an angiotensin receptor-neprilysin inhibitor where suitable, otherwise an ACE inhibitor or an angiotensin receptor blocker. These lower the pressure the heart pumps against.
- A beta-blocker: slows the heart, lowers the strain of adrenaline on the muscle, and improves survival.
- A mineralocorticoid receptor antagonist such as spironolactone or eplerenone: blocks aldosterone, reducing fluid retention and scarring.
- An SGLT2 inhibitor such as dapagliflozin or empagliflozin: originally a diabetes drug, now recommended irrespective of diabetes status.
SGLT2 inhibitors across the ejection fraction spectrum
This class changed the picture for the preserved and mildly reduced groups, which had few proven options. Pooled trial evidence shows a consistent reduction in heart failure hospitalizations across the whole ejection fraction range, with better symptom scores. The effect on cardiovascular death is clear when the ejection fraction is reduced but not established when it is preserved, where the benefit is mainly fewer admissions. Because these drugs make the kidneys excrete glucose and sodium, they also lower blood pressure modestly and call for attention to hydration and genital hygiene.
Treatments layered on top
Diuretics such as furosemide relieve congestion but do not extend life; they are dosed to symptoms and weight. Newer non-steroidal aldosterone blockers have extended benefit into the preserved and mildly reduced categories. Devices help selected patients, including an implantable cardioverter-defibrillator or cardiac resynchronization therapy. Correcting iron deficiency and cardiac rehabilitation add measurable benefit.
Lab monitoring once treatment starts
Nearly every drug that helps a failing heart also acts on the kidneys, so the tests repeated while doses rise exist to keep therapy safe rather than to check that it works. A blood draw about one to two weeks after each dose increase, then periodically once stable, is the usual pattern.
| What is measured | Why it is watched | What a change may mean |
|---|---|---|
| Potassium | Renin-angiotensin blockers and aldosterone blockers raise it; loop diuretics lower it | A rise may lead to a dose change or a potassium binder rather than stopping treatment |
| Creatinine and eGFR | Kidney filtration reacts to blood pressure and fluid changes | A small early rise is expected and usually settles; a large or sustained rise is reviewed |
| Sodium | Falls with fluid overload and with high diuretic doses | A low value often signals congestion or over-diuresis, and prompts a dosing review |
| Magnesium | Lost with loop diuretics, and linked to rhythm stability | Low levels are corrected, particularly alongside low potassium |
| NT-proBNP or BNP | Reflects wall stress, sometimes tracked over time | A falling trend is reassuring; single values are interpreted against your own baseline |
| Hemoglobin and iron studies | Anemia and iron deficiency worsen symptoms | Iron replacement can improve exercise capacity and quality of life |
Potassium: the number that most often interrupts treatment
Aldosterone blockers roughly double the chance of a raised potassium level, although severe elevations stay uncommon, so potassium drives dose decisions more than any other value. Current practice favors adjusting the dose or adding a potassium-lowering agent over abandoning a drug that reduces admissions. Our team has written a plain-language guide to potassium blood test results.
Kidney numbers move, and that is often expected
Starting or increasing a renin-angiotensin blocker or an SGLT2 inhibitor commonly causes a modest early fall in filtration that stabilizes and does not signal harm; with SGLT2 inhibitors the long-term kidney trajectory is better. Read the trend, not one value. Two companion guides cover creatinine test results and eGFR blood test results.
Sodium, fluid and daily weight
A falling sodium level usually reflects water retained in excess of salt, not a lack of dietary salt, and tends to accompany advanced congestion. Daily weight at home is the simplest early warning: a gain of two to three pounds in a day, or five in a week, suggests fluid building up before breathlessness appears. Our guide explains sodium blood test results.
When to see a doctor
Call emergency services for chest pain lasting more than a few minutes, severe breathlessness at rest, breathlessness that wakes you and forces you upright, fainting, or coughing pink frothy sputum. Contact your care team within a day or two for weight gain of five pounds in a week, new or worsening swelling, needing extra pillows to sleep, dizziness after a dose change, or a marked drop in walking distance. The CDC lists the warning signs and risk factors of heart failure in plain terms.
Latest scientific advances
Research over the past three years has mostly clarified how existing treatments should be used. Here is what the strongest recent evidence says, and what it means in practice.
SGLT2 inhibitors help across the whole ejection fraction range
A large 2024 pooled analysis of fifteen trials, covering more than one hundred thousand people with heart failure, diabetes, kidney disease or artery disease, found these drugs cut first hospital admissions for heart failure by roughly a quarter to a third in every group studied. A 2025 review focused on preserved ejection fraction reached the same conclusion, with a small but real gain in quality-of-life scores and no clear effect on survival. What this means for you: this class is now part of standard therapy whatever your ejection fraction, and the realistic promise is fewer hospital stays and easier days rather than a longer life.
Symptom benefit appears early
A review pooling fourteen randomized trials, which are studies where treatment is assigned by chance so the groups are comparable, found a consistent improvement in patient-reported quality of life across all ejection fraction categories, visible as early as two weeks after starting. What this means for you: you may notice easier breathing and more energy within the first month, before any change shows on a scan.
Aldosterone blockers work differently depending on your class
An individual-patient analysis published in 2024, combining four trials and nearly fourteen thousand participants, showed this drug family reduces cardiovascular death and heart failure hospitalization across the ejection fraction range, with a larger benefit when the ejection fraction is reduced. In the preserved and mildly reduced groups the gain was mainly fewer hospitalizations. The trade-off was quantified too: raised potassium was about twice as common on treatment, though seriously high levels stayed rare, while low potassium became about half as frequent. What this means for you: expect potassium checks after starting or increasing this medication, and read a raised value as a reason to adjust rather than to stop.
Raised potassium is increasingly managed without dropping therapy
A 2025 systematic review of more than eighty studies found about one in ten people on renin-angiotensin blockade develop a high potassium level, most often on combinations including an aldosterone blocker. Newer potassium-binding medicines, which trap potassium in the gut so it leaves in the stool, let roughly a third more patients stay on their full protective dose. What this means for you: a high potassium result no longer means automatically losing a drug that keeps you out of hospital.
An unexpected side benefit on blood sugar
A 2025 analysis pooling trial data found people with heart failure or kidney disease taking an SGLT2 inhibitor were about a third less likely to develop diabetes during follow-up. This comes from secondary analyses rather than a trial designed to answer the question, so it is a promising bonus, not a reason to prescribe. What this means for you: one medication may be doing more than one job.
Routine fluid restriction has lost its evidence base
A 2026 systematic review of four randomized trials found no benefit from restricting fluid intake on survival, hospital admissions or natriuretic peptide levels, and more distressing thirst. The trials were small and mostly at risk of bias, so this is a signal rather than a verdict. What this means for you: blanket advice to limit all drinks is no longer routine, though your clinician may still restrict fluids for a low sodium level or severe congestion. Do not change an individual instruction on your own.
Glossary
| Term | Definition |
|---|---|
| Ejection fraction | The percentage of blood the main pumping chamber pushes out with each beat. A normal value is roughly 55 to 70 percent. |
| BNP and NT-proBNP | B-type natriuretic peptide and its inactive fragment. Both rise when the heart chambers are stretched, and both are measured in a blood sample. |
| HFrEF | Heart failure with reduced ejection fraction, defined as 40 percent or below. The muscle contracts too weakly. |
| HFpEF | Heart failure with preserved ejection fraction, defined as 50 percent or above. The chamber squeezes normally but is stiff and fills poorly. |
| Guideline-directed medical therapy | The combination of drug classes that clinical trials have shown to reduce hospital admissions and deaths in heart failure. |
| SGLT2 inhibitor | Sodium-glucose cotransporter 2 inhibitor. A tablet that makes the kidneys excrete glucose and sodium, now used in heart failure with or without diabetes. |
| Mineralocorticoid receptor antagonist | A drug that blocks the hormone aldosterone, reducing fluid retention and scarring of the heart muscle. Spironolactone is the best-known example. |
| Hyperkalemia | A blood potassium level above the normal range. It can affect heart rhythm and is monitored during heart failure treatment. |
| eGFR | Estimated glomerular filtration rate, a calculated figure showing how well the kidneys filter blood. |
| Echocardiogram | An ultrasound scan of the heart that shows chamber size, valve function and how forcefully the muscle contracts. |
Frequently asked questions
Can a normal BNP result rule out heart failure completely?
A normal result makes untreated heart failure unlikely, which is the main reason the test is ordered. It is not absolute. Obesity lowers natriuretic peptide levels, so a person with a high body mass index can have a value inside the reference range despite genuine heart failure. Someone already taking heart failure medication may also test lower than they would have at diagnosis. If your symptoms are typical and persistent, your clinician may still request an echocardiogram regardless of the blood result. The test is a filter, not a final answer.
What are the four stages of heart failure?
Staging describes progression and differs from the ejection fraction classes. Stage A covers people at risk, for example with high blood pressure or diabetes, who have no structural heart change and no symptoms. Stage B means a structural abnormality such as a reduced ejection fraction is present but symptoms have not appeared. Stage C is symptomatic heart failure, which is where most diagnoses sit. Stage D is advanced disease with symptoms that persist despite optimal therapy. Stages do not move backward, but symptoms and ejection fraction can improve substantially within a stage.
How often will my blood be tested once treatment starts?
A common pattern is a check roughly one to two weeks after starting a new drug or increasing a dose, focused on kidney function and potassium. Once doses are stable and results are steady, monitoring usually moves to every three to six months, and more often if kidney function is impaired, if you take several interacting medicines, or during illness with vomiting, diarrhea or dehydration. Your own schedule depends on your kidney function and your drug combination, so follow the interval your clinician sets.
Does a rising ejection fraction mean the heart failure is cured?
It means the muscle has recovered function, which is a genuinely good outcome and has its own label, heart failure with improved ejection fraction. It does not mean the underlying condition has gone. Studies of people who stopped their medication after recovery found that a substantial share relapsed, which is why therapy is normally continued at the same doses. Any decision to reduce or withdraw treatment belongs with your cardiology team.
Is heart failure hereditary?
Most heart failure results from acquired causes such as coronary artery disease, long-standing high blood pressure, diabetes or valve disease. A minority stems from inherited cardiomyopathies, where a gene variant affects the heart muscle directly. Family screening is generally offered when heart failure appears at a young age, when several close relatives are affected, or when there is a family history of sudden unexplained death. If that pattern fits your family, ask your clinician whether cardiac screening or genetic counseling is appropriate.
Which symptoms mean I should be seen the same day?
Severe breathlessness at rest, breathlessness that wakes you from sleep and forces you to sit upright, chest pain lasting more than a few minutes, fainting, a rapid weight gain of around five pounds within a week, or coughing pink frothy sputum all warrant urgent assessment. Sudden severe breathlessness with chest pain should be treated as an emergency. Slower changes such as gradually reduced walking distance still deserve a call to your care team within a few days.
Sources
- Centers for Disease Control and Prevention — About Heart Failure, 2025 — cdc.gov
- MedlinePlus, National Library of Medicine — Natriuretic Peptide Tests (BNP, NT-proBNP), 2025 — medlineplus.gov
- Mayo Clinic — Heart failure: diagnosis and treatment, 2025 — mayoclinic.org
- Eurasian Society of Heart Failure and Turkish Association of Family Medicine — Guideline for the Use of Natriuretic Peptides in the Early Diagnosis and Management of Heart Failure in Primary Care — Balkan Medical Journal, 2025 — PMC11881534
- Usman MS, Bhatt DL, Hameed I, et al. — Effect of SGLT2 inhibitors on heart failure outcomes and cardiovascular death across the cardiometabolic disease spectrum: a systematic review and meta-analysis — The Lancet Diabetes and Endocrinology, 2024 — doi.org/10.1016/S2213-8587(24)00102-5
- Minisy MM, Abdelaziz A — The role of SGLT2 inhibitors in heart failure with preserved ejection fraction: a systematic review and meta-analysis of randomized controlled trials — BMC Cardiovascular Disorders, 2025 — doi.org/10.1186/s12872-025-05127-3
- Shah YR, Turgeon RD — Impact of SGLT2 inhibitors on quality of life in heart failure across the ejection fraction spectrum: systematic review and meta-analysis — CJC Open, 2023 — doi.org/10.1016/j.cjco.2023.12.002
- Jhund PS, Talebi A, Henderson AD, et al. — Mineralocorticoid receptor antagonists in heart failure: an individual patient level meta-analysis — The Lancet, 2024 — doi.org/10.1016/S0140-6736(24)01733-1
- Huang N, Xu Y, Liu C, et al. — Novel potassium binders in reduction of hyperkalemia and optimization of RAAS inhibitor treatment in patients with chronic kidney disease or heart failure: a systematic review and meta-analysis — Drugs, 2025 — doi.org/10.1007/s40265-025-02198-6
- Ostrominski JW, Højbjerg Lassen MC, Claggett BL, et al. — Sodium-glucose co-transporter 2 inhibitors and new-onset diabetes in cardiovascular or kidney disease — European Heart Journal, 2025 — doi.org/10.1093/eurheartj/ehae780
- Herrmann JJ, van Berlo R, Brunner-La Rocca HP, et al. — Fluid restriction in patients with heart failure: a systematic review — Heart, 2026 — doi.org/10.1136/heartjnl-2025-326784
Further reading
- Complete blood count results explained
- Urine electrolyte results explained
- Magnesium blood test results explained
- Ferritin and iron storage levels explained
- High cholesterol causes and treatments
Understand your lab results with BloodSense
A heart failure diagnosis produces a dense report: natriuretic peptides, kidney filtration, potassium, sodium, hemoglobin and thyroid values, each with its own reference range. BloodSense reads that report with you, explains what a BNP or NT-proBNP figure represents, puts creatinine, eGFR and potassium in context, and flags which values are worth raising at your next appointment. It helps you understand your results and prepare better questions; it does not diagnose, and it does not replace your doctor.
